Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

@article{Cavo2010BortezomibWT,
  title={Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.},
  author={Michele Cavo and Paola Tacchetti and Francesca Patriarca and Maria Teresa Petrucci and Lucia Pantani and Monica Galli and Francesco Di Raimondo and Claudia Crippa and Elena Zamagni and Antonio Palumbo and Massimo Offidani and P. Poggi – Corradini and Franco Narni and Antonio Spadano and Norbert Pescosta and Giorgio Lambertenghi Deliliers and Antonio Ledda and Claudia Cellini and Tommaso Caravita and Patrizia Tosi and Michele Baccarani},
  journal={Lancet},
  year={2010},
  volume={376 9758},
  pages={2075-85}
}
BACKGROUND Thalidomide plus dexamethasone (TD) is a standard induction therapy for myeloma. We aimed to assess the efficacy and safety of addition of bortezomib to TD (VTD) versus TD alone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma. METHODS Patients (aged 18-65 years) with previously untreated symptomatic myeloma were enrolled from 73 sites in Italy between May, 2006, and April, 2008, and data… CONTINUE READING
Highly Influential
This paper has highly influenced 19 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 293 extracted citations

Similar Papers

Loading similar papers…